Top Precision Medicine Oncology Companies

Published: September 2024

Cancer is recognized as one of the deadliest diseases, accounting for an alarming global toll of approximately 20 million new cases and 10 million fatalities. According to the World Health Organization, the cancer burden is anticipated to rise by nearly 60 % by 2040. Currently, several conventional approaches, including surgery, radiation therapy, chemotherapy and nonconventional or complementary therapeutic methods, including hormone therapy, immunotherapy and nanotherapy are available for treating these causative variables. However, these approaches are incompetent for dealing with intrinsic carcinogenic genetic abnormalities, owing to the fact that these irregularities are unique to each individual patient. In order to address this, precision medicine, often known as personalized medicine, emerged as a possible solution, which utilizes genomic knowledge to provide gene-targeted diagnostics and therapeutics. The concept of precision medicine takes into account the tumor features, genetic data, lifestyle and environmental effects to provide tailored medicines and holds significant potential in treating oncological disorders by shifting away from a one-size-fits-all approach.

We analyzed around 375 commercialized, clinical and preclinical oncology precision medicines being developed by over 125 precision medicine oncology companies. In this article, discover seven top precision oncology companies and their strength in the oncology precision medicine market.

With advancements in genome profiling, precision medicine is rapidly transforming the dimensions of cancer care and management. Precision medicine in oncology, also referred to as precision oncology, employs genetic testing to determine the genetic characteristics of the patient’s cancerous tumor and customizes the best-suited treatment option. The method correlates the information from the diagnostic test with the medical records of the patient using various emerging technologies, such as next generation sequencing, artificial intelligence, computational biology, machine learning algorithms and digital biomarkers. The incorporation of such technologies aids in the improvement of omics-based studies, enabling the oncologists to refine treatment and prevention strategies for their patients.

Roots Analysis has conducted an exhaustive study on Oncology Precision Medicine Market featuring the current market landscape and future opportunity for the companies engaged in developing oncology precision medicines, over a span of 11 years.

Below, we have listed (in alphabetical order), the top seven precision medicine oncology companies

AstraZeneca
Genentech
Jiangsu Hengrui Pharmaceuticals
Johnson & Johnson Innovative Medicine
Novartis
Pfizer
SpringWorks Therapeutics

Precision Medicine Oncology Companies

Interested in exploring all 125+ Precision Medicine Oncology Companies and their recent initiatives?

Discover Below the Details on 7 Top Precision Medicine Oncology Companies

Let us deep dive to understand the activity of the 7 top precision medicine oncology companies (having more than six drugs either in commercialized or clinical stage of development) engaged in the domain of oncology precision medicine. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

90% of the Drugs Developed by AstraZeneca are Precision Medicines Intended for the Treatment of Various Oncological Indications

1. AstraZeneca

AstraZeneca is a leading biopharmaceutical company involved in the development and commercialization of prescription drugs across three operating segments, namely BioPharmaceuticals, Rare Diseases and Oncology. Within oncology, the company primarily focuses on discovering and developing novel therapeutics for blood cancer, breast cancer, gastrointestinal cancer, gynecological / genitourinary cancer and lung cancer. Additionally, the company has taken several initiatives to integrate advanced technologies, such as artificial intelligence in order to streamline and support the clinical trials of its precision oncology drug candidates.

AstraZeneca: Company Overview

Particulars	Specifications
Company Logo
Year of Establishment	1999
Number of Employees	10,000+
Headquarters	England, UK
Oncology Precision Medicines	Anastrozole Durvalumab Fam-trastuzumab deruxtecan-nxk Gefitinib Olaparib Osimertinib Savolitinib Savolitinib + (Osimertinib) Vandetanib

The company is actively engaging in several prominent conferences, including the European Society for Medical Oncology (ESMO) Congress, scheduled for October 20-24, 2023, in Madrid, Spain, and the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer, which took place in August 2023 in Singapore. These events provide a platform for showcasing their drugs, Enhertu, Imfinzi, and Tagrisso.

Further details on recent initiatives taken by AstraZeneca and other precision medicine oncology companies have been provided in detail in the report.

In May 2024, FDA Granted Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

2. Genentech

Genentech, a part of the Roche group, is a leading biotechnology firm which specializes in the delivery of novel therapeutic entities for patients with life threatening medical disorders. With an experience of more than 45 years, the company has developed a broad portfolio of drugs in various therapeutic areas such as infectious diseases, immunology, neuroscience, ophthalmology and oncological disorders. Additionally, the company is leveraging advanced technologies such as genome sequencing to discover and develop precision medicines for various therapeutic indications across the oncological domain.

Genentech: Company Details

Particulars	Specifications
Company Logo
Year of Establishment	1976
Number of Employees	10,001+
Headquarters	California, US
Oncology Precision Medicines	Ado-trastuzumab emtansine Alectinib Atezolizumab Bevacizumab Cobimetinib Cobimetinib + (Vemurafenib) GDC-1971 / Migoprotafib / RO7517834 / RLY-1971 Vismodegib

It is worth noting that Genentech is actively incorporating big data analytics to identify genomic patterns in cancer patients for the development of target-specific medicines.

Further details on recent initiatives taken by Genentech and other precision medicine oncology companies have been provided in detail in the report.

Jiangsu Hengrui Pharmaceuticals has Developed Two Precision Therapeutics for Breast, Gastrointestinal and Lung Cancer which are Currently in the Late-stages of Clinical Trial Evaluation

3. Jiangsu Hengrui Pharmaceuticals

Jiangsu Hengrui Pharmaceuticals is a global pharmaceutical company known for manufacturing high-quality therapeutic drugs. The company has a robust research and drug development pipeline for various therapeutic areas, such as autoimmune disorders, cardiovascular disorders, oncological disorders and infectious diseases.

Jiangsu Hengrui Pharmaceuticals: Company Overview

Particulars	Specifications
Company Logo
Year of Establishment	1970
Number of Employees	10,000+
Headquarters	Lianyungang, China
Oncology Precision Medicines	Apatinib / Rivoceranib Apatinib / Rivoceranib Apatinib / Rivoceranib + (Camrelizumab) Pyrotinib Pyrotinib + (Capecitabine) Pyrotinib + (SHR-A1811) Pyrotinib + (Trastuzumab, Docetaxel)

Jiangsu Hengrui Pharmaceuticals is striving to improve the quality of life for mankind through their consistent efforts in the research, development, manufacturing and commercialization of novel therapeutics. In October 2018, the company established a partnership with Elevar Therapeutics to conduct a clinical study for assessing the effectiveness of Aitan, a precision oncology drug, in patients with advanced hepatocellular carcinoma.

Further details on recent initiatives taken by Jiangsu Hengrui Pharmaceuticals and other precision medicine oncology companies have been provided in detail in the report.

Johnson & Johnson Innovative Medicine, Previously Known as Janssen Pharmaceuticals was Acquired by Johnson & Johnson in 1961

4. Johnson & Johnson Innovative Medicine

Johnson & Johnson Innovative Medicine specializes in the production of innovative therapeutic solutions for various medical disorders. The firm operates through three segments namely Consumer Health, Pharmaceutical and MedTech. Within the Pharmaceutical division, the company offers a diverse pipeline of drugs with a primary focus on the areas such as cardiovascular, immunology, infectious diseases, neuroscience, oncology, and pulmonary hypertension. It is worth highlighting that in recent years the firm has made significant investments in research and development of precision medicines targeting oncological disorders. This has led to the successful commercialization of eight drugs for different oncological indications such as bladder cancer, blood / hematologic cancer, lung cancer and reproductive cancer.

Johnson & Johnson Innovative Medicine: Company Overview

Particulars	Specifications
Company Logo
Year of Establishment	1953
Number of Employees	10,000+
Headquarters	New Jersey, US
Oncology Precision Medicines	Abiraterone Acetate Amivantamab-vmjw Bortezomib Ciltacabtagene autoleucel Daratumumab Erdafitinib Ibrutinib Teclistamab-cqyv

The company is actively participating in several key conferences, including the European Society for Medical Oncology (ESMO) Congress, set to take place from October 2023, in Madrid, Spain; the 20th International Myeloma Society (IMS) Annual Meeting in September 2023 in Greece; and the European Hematology Association (EHA) 2023 Congress. Additionally, they attended the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which occurred in May 2023 in both Germany and the U.S. These events serve as vital platforms for showcasing their drugs, including Balversa, Carvykti, DARZALEX, Rybrevant and TECVAYLI.

Further details on recent initiatives taken by Johnson & Johnson Innovative Medicine and other precision medicine oncology companies have been provided in detail in the report.

Novartis is Innovating New Techniques to Extract Stem Cells from the Patients’ Skin in Order to Reprogram the Cells and Discover Novel Drug Targets, Strengthening their Current Precision Medicines Portfolio

5. Novartis

Novartis is one of the largest multinational healthcare companies in the world, widely recognized for the discovery and development of breakthrough therapies for hard-to-treat health conditions. The firm leverages innovative technologies and strategies to produce high-value medicines that have consistently improved the patient’s quality of life over the past two decades. Additionally, with a comprehensive understanding of cancer biology, the firm strives to build a robust pipeline of oncology precision medicines.

Novartis: Company Overview

Particulars	Specifications
Company Logo
Year of Establishment	1996
Number of Employees	10,000+
Headquarters	Basel,of oncology
Oncology Precision Medicines	Alpelisib Asciminib Capmatinib Ceritinib Dovitinib Dovitinib Everolimus Imatinib Letrozole Midostaurin Nilotinib Ribociclib + (Aromatase Inhibitor) Tisagenlecleucel

In June 2024, Novartis announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to Scemblix® (asciminib) for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CML-CP).

Further details on recent initiatives taken by Novartis and other precision medicine oncology companies have been provided in detail in the report.

Pfizer has Successfully Developed and Commercialized 17 Precision Therapeutics for the Treatment of Different Oncological Disorders

6. Pfizer

Pfizer is a leading biopharmaceutical company engaged in research and development of revolutionary therapeutics to improve and transform the life of patients suffering from various medical conditions. The company offers a robust pipeline of drugs and vaccines for a wide range of therapeutic areas, such as oncological disorders, infectious and rare diseases. Within the oncology segment, the company primarily focuses on precision medicine, tumor targeted therapeutics, tumor cell biology, integrative biotechnology and immuno-oncology.

Pfizer: Company Overview

Particulars	Specifications
Company Logo
Year of Establishment	1849
Number of Employees	10,000+
Headquarters	New York, US
Oncology Precision Medicines	Avelumab Axitinib + (Avelumab / Pembrolizumab) Bosutinib Brentuximab vedotin Crizotinib Dacomitinib Elranatamab Encorafenib + (Cetuximab) Encorafenib, Binimetinib Enzalutamide Exemestane Glasdegib Lorlatinib Palbociclib + (Aromatase Inhibitor / Fulvestrant) Sunitinib Talazoparib Temsirolimus

In May 2023, Pfizer entered into a strategic partnership with Thermo Fisher Scientific to augment the access to next generation sequencing-based tests for breast and lung cancer across Latin America and Middle East and North Africa.

Further details on recent initiatives taken by Pfizer and other precision medicine oncology companies have been provided in detail in the report.

In the Recent Years, SpringWorks Therapeutics has Successfully Advanced its Two Lead Drug Candidates, Mirdametinib and Nirogacestat to the Late Stages of Development

7. SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of life-changing medicines for rare diseases and oncological disorders. With the precision-based approach to drug development, the firm has built a robust portfolio of small molecule drugs for various oncology indications ranging from solid tumors to hematologic cancers.

SpringWorks Therapeutics: Company Overview

Particulars	Specifications
Company Logo
Year of Establishment	2017
Number of Employees	51-200
Headquarters	Connecticut, US
Oncology Precision Medicines	Brimarafenib / BGB-3245 Mirdametinib Mirdametinib Mirdametinib + Fulvestrant Mirdametinib + Lifirafenib Nirogacestat Nirogacestat + (Blenrep-belantamab mafodotin) Nirogacestat + (Elranatamab) Nirogacestat + (SEA-BCMA / ABBV-383/ Linvoseltamab) Nirogacestat + (Teclistamab)

Further details on recent initiatives taken by SpringWork Therapeutics and other precision medicine oncology companies have been provided in detail in the report.

What About the Other Precision Medicine Oncology Companies Around the World?

The above presentation features seven top precision medicine oncology companies selected from a pool of over 125 players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com

Sources